Prevention of Vaccinia Lesions in Rhesus Monkeys by Human Leucocyte and Fibroblast Interferon

Authors:
  • WWW. Weimar
    W. Weimar
  • LSL. Stitz
    L. Stitz
  • ABA. Billiau
    A. Billiau
  • KCK. Cantell
    K. Cantell
  • HSH. Schellekens
    H. Schellekens

Abstract
The prophylactic antiviral activity of systemically administered human interferon preparations was tested in 36 rhesus monkeys against vaccinia virus injected into the skin. All 9 control monkeys developed typical vaccinia skin lesions. Eight of 9 monkeys treated with daily i.m. injections of leukocyte inteferon (5 .times. 105 units/kg) from day -1 to day 7 after vaccination were completely protected. No lesions developed after discontinuation of therapy. Administration of the same amounts of leukocyte interferon i.v. was equally effective. Daily i.m. injections of lower doses of leukocyte interferon (1.25 .times. 105 units/kg; 0.5 .times. 105 units/kg) decreased the severity of the skin lesions. Lesion scores correlated inversely with the dose of interferon. Four of 6 animals receiving daily i.m. injections of fibroblast interferon (5 .times. 105 units/kg) and 1 of 3 animals treated i.v. with the same dose were protected against vaccinia virus, and the lesions in the other monkeys were smaller. I.m. injections of 5 .times. 105 units/kg of fibroblast interferon or 1.25 .times. 105 units/kg of leukocyte interferon resulted in comparable serum levels and had comparable efficacy in reducing lesion scores.